Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

XORTX Therapeutics Inc

XRTX.V ✓ COMPLIANT ☆ Track — members

TSX Venture · Healthcare · Biotechnology & Medical Research ·

Canada Micro Cap Analyst: N/A

Last Close

$2.00

▲ +0.00%

Market Cap $3.63M · Vol 50

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$3.63M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

0.00

Momentum

Beta

0.09

vs Market

52W High

$7.10

N/A below

52W Low

$1.75

N/A above

Volume

Avg 301

P/B

1.87

Price-to-book

ROE

N/A

Return on equity

Free Float

92.17%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, XORTX Therapeutics Inc (XRTX.V) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does XRTX.V pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-0.71%

-5.76%

+0.72%

-2.46%

YTD

-27.79%

-52.88%

-92.79%

-98.76%

Financials & Valuation

TTM · Annual

Total Revenue	$0.00
Net Income	$-2,656,300.00
Revenue Growth (YoY)	N/A
Gross Margin	N/A
Operating Margin	N/A
Net Profit Margin	N/A
ROE	N/A
ROA · ROIC	-78.38% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	N/A
P/B	1.87
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	1.82M

Technical Indicators

50-Day SMA	$2.11
200-Day SMA	$2.44
RSI (14)	0.00
Beta	0.09
52-Week High	$7.10
52-Week Low	$1.75

Volume Today	50
Avg Daily Volume (30D)	301
Relative Volume	0.17x
Volatility (10D)	7.19
Volatility (30D)	14.09
Free Float	92.17%

Analyst Consensus

N/A

Current Price $2.00

Mean Target N/A

52W Low$1.75 52W High$7.10

Current

Target

$1.75 $7.10

Current Analyst target

· 0 analysts

Identifiers

ExchangeTSX Venture

FIGIBBG009J96Z06

ISINCA98420Q4051

CountryCanada

Sub-IndustryBio Therapeutic Drugs

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

XORTX Therapeutics Inc. is a pharmaceutical company. The Company is engaged in developing medications that improve the quality of life and health of individuals with gout and other important diseases. It has three clinically advanced products in development: its lead program, XRx-026 program for the treatment of gout; XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD); and XRx-101 for acute kidney and other acute organ injury associated with respiratory virus infections. In addition, the Company is developing XRx-225, a pre-clinical stage program for Type II diabetic nephropathy. It is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit the production of uric acid. The XRx-026 program is designed to decrease the chronically high serum uric acid concentration in the blood (SUA) by inhibiting the production of uric acid by the xanthine oxidase enzyme by administering a xanthine oxidase inhibitor-oxypurinol.